異基因造血幹細胞移植（HSCT）是治療各類血液或造血器官疾病的有效方法。移植物抗宿主病（GVHD）是由於免疫系統過度活躍攻擊正常宿主組織所致。它可發生於肝臟、皮膚、眼黏膜表面、胃腸道及生殖器。 眼部GVHD在HSCT後發生於30-70%的患者。
適應症：Graft Vs Host Disease、Haematological Malignancy、Cancer
收案條件
納入條件
- Patient aged 18 or above
- Underwent allogeneic HSCT in QMH in the two-year recruitment period
排除條件
- Underwent autologous HSCT
- Patient unable to attend follow-up visits
- Family Control Subjects The research team will invite an accompanying family member to be the family control. Microbiome and tear samples will be collected for comparison. The sample collection schedule is the same as the corresponding post-HSCT case.
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。